Diverse Institutional Portfolio Growth
Orchard Capital Expands Portfolio With Diverse Investments Across Five Public Companies
Key Points
Pathward Financial shows notably conservative fundamentals in its SEC context: debt-to-equity 0.04, quick ratio 0.81, current ratio 0.82, market cap about $1.74 billion, a P/E of 10.49 and a beta of 0.61, as Orchard Capital Management LLC added 21,144 shares (~$1.84 million) representing about 1.8% of its portfolio. The same article also notes other hedge funds taking positions in Pathward in Q2, including BlackRock’s new stake and Bank of America’s sizable prior buildup.
North American Construction Group remains a meaningful conviction for Orchard: the fund bought 226,537 shares worth about $3.013 million, making up roughly 2.9% of Orchard’s portfolio and ranking as its 12th biggest holding; Orchard reportedly owned about 0.81% of NOA as of the filing.
Metallus Inc. is another sizable, strategic addition with 136,651 shares valued at about $2.554 million (roughly 2.5% of Orchard’s portfolio, 17th biggest). The stock drew external commentary from research firms, including Zacks raising MTUS from ‘strong sell’ to ‘hold’ on April 27, along with KeyCorp’s sector-weight stance and Weiss Ratings’ upgrade.
Ducommun Incorporated is a top-five holding after Orchard’s purchase of 23,718 shares for about $4.393 million (roughly 4.3% of the portfolio). The move coincides with a high concentration of hedge fund ownership in DCO (about 92.15%), underscoring broad institutional interest in the stock.
Intellia Therapeutics attracts a mid-single-digit stake for Orchard: 79,503 shares valued at about $1.345 million (around 1.3% of the portfolio), ranking it as Orchard’s 26th largest position. The activity sits amid diverse hedge fund activity in NTLA, including AQR Capital Management’s large gain in Q1 and ongoing involvement from UBS AM and Cetera, with hedge funds accounting for approximately 88.77% of NTLA stock.
Orchard Capital Management LLC expanded its stock portfolio in the second quarter with new stakes across five diverse companies. The fund bought roughly 21,144 shares of Pathward Financial for about $1.84 million, 226,537 shares of North American Construction Group for roughly $3 million, and 136,651 shares of Metallus for about $2.55 million, according to Watchlist News and Ticker Report. Orchard also invested $4.39 million in Ducommun and $1.35 million in Intellia Therapeutics, signaling confidence across financial services, energy, aerospace, and biotech sectors.
Pathward Financial Draws Conservative Banking Play
Orchard's $1.84 million position in Pathward Financial represents about 1.8% of its portfolio, according to Watchlist News. The savings and loans company shows strong financial fundamentals: a debt-to-equity ratio of just 0.04 and a price-to-earnings ratio of 10.49. Pathward trades with a market cap of $1.74 billion and carries a low beta of 0.61, meaning it moves less than the broader market. Other major investors like BlackRock and Bank of America also took positions in the stock during the quarter.
North American Construction Group Marks Growing Conviction
Orchard Capital bought 226,537 shares of North American Construction Group for approximately $3.01 million in Q2, according to Watchlist News. The position ranks as the fund's 12th largest holding at roughly 2.9% of its portfolio. Orchard now owns about 0.81% of the oil and gas company, signaling meaningful conviction in the energy sector. The stock attracts diverse institutional attention across hedge funds and asset managers.
Metallus and Ducommun Emerge as Top Holdings
Orchard's $2.55 million stake in Metallus Inc. adds 136,651 shares to its holdings, representing roughly 2.5% of the fund's portfolio and ranking as its 17th biggest position, per Watchlist News. Research firms took notice: Zacks upgraded Metallus from 'strong sell' to 'hold' in late April. Separately, Orchard invested $4.39 million in Ducommun Incorporated, purchasing 23,718 shares that now make up roughly 4.3% of its portfolio—a top-five holding. Ducommun's stock shows extreme institutional concentration, with hedge funds owning approximately 92.15% of the company.
Intellia Therapeutics Rounds Out Biotech Exposure
Orchard Capital invested $1.35 million in Intellia Therapeutics through a purchase of 79,503 shares in Q2, according to Ticker Report. The position ranks as the fund's 26th largest holding at around 1.3% of its portfolio. Intellia's stock shows strong hedge fund ownership at approximately 88.77%, with major investors like AQR Capital Management and UBS Asset Management also holding sizable stakes. The biotech move demonstrates Orchard's diversified, opportunistic approach across multiple sectors.
Sentiment
Mostly PositivePublishers
13
Articles
4
Reach
17
